SLC5A2 and chronic kidney disease: This study is the first study in the literature that highlights the impact of an SGLT2 inhibitor on CABG patients with/without T2DM and with/without CKD undergoing a rehabilitation program and compares the influence of an SGLT2 inhibitor on H-FABP levels.